Nutex Health (NUTX) Stock: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$213.02
-5.38 (-2.46%)
âŧ
5d:
+0.64%
30d:
+11.73%
90d:
+16.18%
WAIT
LOW Confidence
Analysis Updated: Oct 7, 2026 12:00 AM ET
Earnings: Nov 18, 2026
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NUTX is fairly priced but lacks strong directional signals. At 2.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NUTX is fairly priced but lacks strong directional signals. At 2.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$379.94
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$235.91
9.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $213.02, which is considered slightly high relative to its 30-day fair value range of $195.85 to $216.90. The stock's valuation (Forward PE: 7.6) is in line with its historical norms (7.0). At these levels, the market is pricing in 2.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NUTX is in a strong uptrend. Immediate support is located at $198.25, while resistance sits at $226.16.
Market Sentiment: NUTX scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $288.20 (+35.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUTX is in a strong uptrend. Immediate support is located at $198.25, while resistance sits at $226.16.
Market Sentiment: NUTX scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $288.20 (+35.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$195.85 -
$216.90
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
43.8%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.3% below Wall St target ($288.20)
- NEUTRAL: Market pricing in 2.7% annual earnings growth - fairly valued
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$195.85 -
$216.90
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$198.25
Resistance Level
$226.16
Current Trend
Strong Uptrend
Technical data as of
Oct 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.64
Wall Street Target
$288.20
(+35.3%)
Revenue Growth (YoY)
-13.6%
Earnings Growth (YoY)
95.9%
Profit Margin
21.2%
Valuation Premium vs History
+2.7% premium
PE vs Historical
7.6 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.7%
(market-implied from PE analysis)
1-Year Target
$218.77
(+3%)
2-Year Target
$224.68
(+6%)
3-Year Target
$230.74
(+8%)
3-Yr Target (if PE normalizes)
(PE: 8â7)
PE COMPRESSION
$211.34
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.7, Growth: 28.1%)
$553.71
(+160%)
Base:
(SPY PE: 7.6, Growth: 28.1%)
$214.82
(+1%)
Bear:
(PE: 6.5, Growth: 28.1%)
$182.60
(-14%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 8.65 | Current EPS (TTM): $25.24
Bull Case
$265.29
(+25%)
Analyst growth 10.4%, PE expands to 9.5
Base Case
$241.17
(+13%)
Market implied 10.4%, PE stable at 8.7
Bear Case
$148.51
(-30%)
Severe decline -20.0%, PE contracts to 7.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 07, 2026 7:18 PM ET
Data refreshes hourly during market hours. Next update: 8:18 PM
Data refreshes hourly during market hours. Next update: 8:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare CorporaâĻ |
STRONG BUY
23 analysts |
$285 | 60 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
26 analysts |
$454 | 53 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
16 analysts |
$24 | 60 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
13 analysts |
$148 | 58 HOLD |
|
ADUS
Addus HomeCare CorporatiâĻ |
STRONG BUY
14 analysts |
$134 | 64 BUY |
